Andrew is a London-based journalist who has been writing about pharma, biotech and healthcare for over 20 years.
He writes on a range of topics, including biopharma R&D and commercial issues, digital healthcare and issues affecting patients and global healthcare systems, especially the UK’s NHS.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Neil Woodford’s fall from grace and Brexit dragged on an otherwise buoyant sector.
Once a pariah because of its price gouging, the new approval represents a change of tack from Horizon.
Often dismissed as a meeting of the global elite, Davos is nevertheless a chance for biopharma leaders to take part in ‘big picture’ debates
Neuroscience could be this decade’s big growth story, but clinical and market access challenges differ to oncology.